{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:45:34Z","timestamp":1790891134266,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.modpat.2024.100424","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T06:28:32Z","timestamp":1705818512000},"page":"100424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2"],"prefix":"10.1016","volume":"37","author":[{"given":"Jessica M.","family":"Posada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Yakirevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennady","family":"Bratslavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Mega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan J.","family":"Golijanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Pavlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.P.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Danziger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S.","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smruthy","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-5293","authenticated-orcid":false,"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.modpat.2024.100424_bib1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.humpath.2006.05.009","article-title":"Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications","volume":"37","author":"Lopez-Beltran","year":"2006","journal-title":"Hum Pathol"},{"issue":"8","key":"10.1016\/j.modpat.2024.100424_bib2","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.humpath.2009.11.018","article-title":"Invasive micropapillary urothelial carcinoma of the bladder","volume":"41","author":"Lopez-Beltran","year":"2010","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1016\/j.modpat.2024.100424_bib3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3109\/00313025.2010.522173","article-title":"Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases","volume":"42","author":"Comperat","year":"2010","journal-title":"Pathology"},{"issue":"5","key":"10.1016\/j.modpat.2024.100424_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.urolonc.2019.10.013","article-title":"Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma","volume":"38","author":"Yang","year":"2020","journal-title":"Urol Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.modpat.2024.100424_bib5","doi-asserted-by":"crossref","first-page":"S1539","DOI":"10.21037\/tcr.2016.12.56","article-title":"Evolving concepts of micropapillary variant urothelial carcinoma","volume":"5","author":"Monn","year":"2016","journal-title":"Transl Cancer Res"},{"issue":"5","key":"10.1016\/j.modpat.2024.100424_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/MOU.0b013e328363e415","article-title":"Should histologic variants alter definitive treatment of bladder cancer?","volume":"23","author":"Willis","year":"2013","journal-title":"Curr Opin Urol"},{"issue":"2","key":"10.1016\/j.modpat.2024.100424_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.clgc.2020.10.002","article-title":"Response to neoadjuvant chemotherapy and survival in micropapillary urothelial carcinoma: data from a tertiary referral center and the surveillance, epidemiology, and end results (SEER) program","volume":"19","author":"Diamantopoulos","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.modpat.2024.100424_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A\u00a0high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2024.100424_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2018.05.022","article-title":"Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype","volume":"80","author":"Zinnall","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.modpat.2024.100424_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2013.00086","article-title":"Activating mutations in ERBB2 and their impact on diagnostics and treatment","volume":"3","author":"Herter-Sprie","year":"2013","journal-title":"Front Oncol"},{"issue":"45","key":"10.1016\/j.modpat.2024.100424_bib11","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.modpat.2024.100424_bib12","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100424_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","article-title":"Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2","volume":"51","author":"Oudard","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.modpat.2024.100424_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2-positive metastatic bladder cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.modpat.2024.100424_bib15","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2015.66.3047","article-title":"Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations","volume":"34","author":"Choudhury","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.modpat.2024.100424_bib16","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.modpat.2024.100424_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne(R)CDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.modpat.2024.100424_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"issue":"6","key":"10.1016\/j.modpat.2024.100424_bib19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A\u00a0novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J\u00a0Mol Diagn"},{"issue":"10106","key":"10.1016\/j.modpat.2024.100424_bib20","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"7463","key":"10.1016\/j.modpat.2024.100424_bib21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.modpat.2024.100424_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/srep42713","article-title":"Her2 alterations in muscle-invasive bladder cancer: patient selection beyond protein expression for targeted therapy","volume":"7","author":"Kiss","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.modpat.2024.100424_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euf.2016.06.007","article-title":"Human epidermal growth factor receptor 2 overexpression in micropapillary and other variants of urothelial carcinoma","volume":"4","author":"Behzatoglu","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"8","key":"10.1016\/j.modpat.2024.100424_bib24","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41379-018-0023-9","article-title":"Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility","volume":"31","author":"Moktefi","year":"2018","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2024.100424_bib25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/modpathol.2013.201","article-title":"Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome","volume":"27","author":"Schneider","year":"2014","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2024.100424_bib26","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.3390\/ijms24043720","article-title":"HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"15_suppl","key":"10.1016\/j.modpat.2024.100424_bib27","article-title":"A\u00a0phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01)","volume":"39","author":"Li","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.modpat.2024.100424_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.438","article-title":"Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC)","volume":"40","author":"Galsky","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.modpat.2024.100424_bib29","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.2147\/OTT.S247515","article-title":"Response to anti-HER2-based treatment in a patient with bladder adenocarcinoma harboring HER2 amplification and S310F mutation discovered by next-generation sequencing: a case report","volume":"13","author":"Wang","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"6512","key":"10.1016\/j.modpat.2024.100424_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.abe0955","article-title":"Mutational selection in normal urothelium","volume":"370","author":"Rozen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.modpat.2024.100424_bib31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.humpath.2021.04.001","article-title":"Molecular pathology of urothelial carcinoma","volume":"113","author":"Lopez-Beltran","year":"2021","journal-title":"Hum Pathol"},{"issue":"24","key":"10.1016\/j.modpat.2024.100424_bib32","doi-asserted-by":"crossref","first-page":"16891","DOI":"10.18632\/oncotarget.24738","article-title":"ATM\/RB1 mutations predict shorter overall survival in urothelial cancer","volume":"9","author":"Yin","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.modpat.2024.100424_bib33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12885-021-08078-y","article-title":"RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer","volume":"21","author":"Manzano","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.modpat.2024.100424_bib34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"7283","key":"10.1016\/j.modpat.2024.100424_bib35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.modpat.2024.100424_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5682078","article-title":"Update on the treatment of metastatic urothelial carcinoma","volume":"2018","author":"Bukhari","year":"2018","journal-title":"ScientificWorldJournal"},{"issue":"1","key":"10.1016\/j.modpat.2024.100424_bib37","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.modpat.2024.100424_bib38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12935-019-0937-4","article-title":"The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors","volume":"19","author":"Hou","year":"2019","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.modpat.2024.100424_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99524-1","article-title":"CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer","volume":"11","author":"Gutiontov","year":"2021","journal-title":"Sci Rep"},{"issue":"6278","key":"10.1016\/j.modpat.2024.100424_bib40","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.modpat.2024.100424_bib41","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 Axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"issue":"6278","key":"10.1016\/j.modpat.2024.100424_bib42","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.modpat.2024.100424_bib43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","article-title":"MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage","volume":"39","author":"Kalev","year":"2021","journal-title":"Cancer Cell"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395224000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395224000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T03:18:29Z","timestamp":1740799109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395224000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0893395224000048"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100424","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100424"}}